Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP561471.RAWV8BRmdpIYeBw5kSDhIHuQh0RpA63GX58Ihpjpg1CP0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP561471.RAWV8BRmdpIYeBw5kSDhIHuQh0RpA63GX58Ihpjpg1CP0130_assertion type Assertion NP561471.RAWV8BRmdpIYeBw5kSDhIHuQh0RpA63GX58Ihpjpg1CP0130_head.
- NP561471.RAWV8BRmdpIYeBw5kSDhIHuQh0RpA63GX58Ihpjpg1CP0130_assertion description "[For a long period of time, the standard therapy for MDS was hematopoietic stem cell transplantation, however DNA methyltransferase inhibitors (DNMT inhibitors) including decitabine (DAC) and azacitidine (AZA), and lenalidomide, a derivative of thalidomide have been highlighted as new chemotherapeutic agents for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP561471.RAWV8BRmdpIYeBw5kSDhIHuQh0RpA63GX58Ihpjpg1CP0130_provenance.
- NP561471.RAWV8BRmdpIYeBw5kSDhIHuQh0RpA63GX58Ihpjpg1CP0130_assertion evidence source_evidence_literature NP561471.RAWV8BRmdpIYeBw5kSDhIHuQh0RpA63GX58Ihpjpg1CP0130_provenance.
- NP561471.RAWV8BRmdpIYeBw5kSDhIHuQh0RpA63GX58Ihpjpg1CP0130_assertion SIO_000772 22571700 NP561471.RAWV8BRmdpIYeBw5kSDhIHuQh0RpA63GX58Ihpjpg1CP0130_provenance.
- NP561471.RAWV8BRmdpIYeBw5kSDhIHuQh0RpA63GX58Ihpjpg1CP0130_assertion wasDerivedFrom befree-20140225 NP561471.RAWV8BRmdpIYeBw5kSDhIHuQh0RpA63GX58Ihpjpg1CP0130_provenance.
- NP561471.RAWV8BRmdpIYeBw5kSDhIHuQh0RpA63GX58Ihpjpg1CP0130_assertion wasGeneratedBy ECO_0000203 NP561471.RAWV8BRmdpIYeBw5kSDhIHuQh0RpA63GX58Ihpjpg1CP0130_provenance.